The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

The pulsed field ablation developer Kardium has collected $250 million in funding to gear up for the commercial expansion of ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Kardium Inc., the developer of the Globe ® Pulsed Field System - an innovative treatment for atrial fibrillation (AF) - has ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, ...

Kardium announced today that it raised $250 million in a new financing round to support the launch of its pulsed field ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...